In contrast, in more aggressive B‐cell malignancies, including diffuse large B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL), responses to single agent BTK inhibitors (BTKi) occur only in subsets of patients and are mostly of brief duration. Here, BTK is linked to diffuse large B-cell lymphoma.